chicksdaddy shares a report from The Security Ledger: The NotPetya malware infection shut down pharmaceutical giant Merck's production of the pediatric vaccine GARDASIL last June, forcing the company to borrow the drug from a stockpile maintained by the U.S. Centers for Disease Control and Prevention to meet demand, The Security Ledger reports. The anecdote was contained in a quarterly filing by Merck with the U.S. Securities and Exchange Commission (SEC) on Friday. That filing also showed that the company continues to suffer financial fallout from the outbreak of the NotPetya malware in June, reducing both sales and revenue for the quarter by hundreds of millions of dollars. In its quarterly 8-k filing, Merck said that revenue for the quarter was "unfavorably impacted" by around $135 million due to "lost sales in certain markets related to the cyber-attack." Sales in the third quarter of 2017 were also reduced by around $240 million, which Merck chalked up to production shutdowns resulting from NotPetya. In a chilling insight into the extent of the disruption the malware caused to Merck's operations, the company disclosed that part of its quarterly losses were linked to the interruption of its production of GARDASIL, a vaccine used to prevent Human Papillomavirus (HPV) which is linked to certain cancers and other diseases. To make up for what it described as "overall higher demand than originally planned," Merck was forced to borrow the vaccine from a stockpile maintained by the U.S. Centers for Disease Control (CDC), the company said.